vs

Side-by-side financial comparison of NEOGENOMICS INC (NEO) and UL Solutions Inc. (ULS). Click either name above to swap in a different company.

UL Solutions Inc. is the larger business by last-quarter revenue ($789.0M vs $190.2M, roughly 4.1× NEOGENOMICS INC). On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (10.6% vs 6.8%). UL Solutions Inc. produced more free cash flow last quarter ($86.0M vs $-6.5M). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (10.3% CAGR vs 8.5%).

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

The UL enterprise is a global private safety company headquartered in Northbrook, Illinois, composed of three organizations, UL Research Institutes, UL Standards & Engagement and UL Solutions.

NEO vs ULS — Head-to-Head

Bigger by revenue
ULS
ULS
4.1× larger
ULS
$789.0M
$190.2M
NEO
Growing faster (revenue YoY)
NEO
NEO
+3.8% gap
NEO
10.6%
6.8%
ULS
More free cash flow
ULS
ULS
$92.5M more FCF
ULS
$86.0M
$-6.5M
NEO
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
10.3%
8.5%
ULS

Income Statement — Q4 2025 vs Q4 2025

Metric
NEO
NEO
ULS
ULS
Revenue
$190.2M
$789.0M
Net Profit
$67.0M
Gross Margin
43.8%
49.7%
Operating Margin
-7.1%
15.0%
Net Margin
8.5%
Revenue YoY
10.6%
6.8%
Net Profit YoY
-17.3%
EPS (diluted)
$0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEO
NEO
ULS
ULS
Q4 25
$190.2M
$789.0M
Q3 25
$187.8M
$783.0M
Q2 25
$181.3M
$776.0M
Q1 25
$168.0M
$705.0M
Q4 24
$172.0M
$739.0M
Q3 24
$167.8M
$731.0M
Q2 24
$164.5M
$730.0M
Q1 24
$156.2M
$670.0M
Net Profit
NEO
NEO
ULS
ULS
Q4 25
$67.0M
Q3 25
$-27.1M
$100.0M
Q2 25
$-45.1M
$91.0M
Q1 25
$-25.9M
$67.0M
Q4 24
$81.0M
Q3 24
$-17.7M
$88.0M
Q2 24
$-18.6M
$101.0M
Q1 24
$-27.1M
$56.0M
Gross Margin
NEO
NEO
ULS
ULS
Q4 25
43.8%
49.7%
Q3 25
42.8%
50.3%
Q2 25
42.6%
49.4%
Q1 25
43.6%
48.4%
Q4 24
44.9%
47.4%
Q3 24
44.6%
49.0%
Q2 24
44.1%
50.1%
Q1 24
41.9%
47.6%
Operating Margin
NEO
NEO
ULS
ULS
Q4 25
-7.1%
15.0%
Q3 25
-14.4%
19.9%
Q2 25
-26.3%
17.9%
Q1 25
-16.6%
15.5%
Q4 24
-10.7%
15.6%
Q3 24
-12.6%
17.8%
Q2 24
-13.3%
17.3%
Q1 24
-19.6%
13.6%
Net Margin
NEO
NEO
ULS
ULS
Q4 25
8.5%
Q3 25
-14.4%
12.8%
Q2 25
-24.9%
11.7%
Q1 25
-15.4%
9.5%
Q4 24
11.0%
Q3 24
-10.5%
12.0%
Q2 24
-11.3%
13.8%
Q1 24
-17.3%
8.4%
EPS (diluted)
NEO
NEO
ULS
ULS
Q4 25
$0.33
Q3 25
$0.49
Q2 25
$0.45
Q1 25
$0.33
Q4 24
$0.40
Q3 24
$0.44
Q2 24
$0.50
Q1 24
$0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEO
NEO
ULS
ULS
Cash + ST InvestmentsLiquidity on hand
$159.6M
$295.0M
Total DebtLower is stronger
$341.9M
$491.0M
Stockholders' EquityBook value
$836.6M
$1.3B
Total Assets
$1.4B
$2.9B
Debt / EquityLower = less leverage
0.41×
0.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEO
NEO
ULS
ULS
Q4 25
$159.6M
$295.0M
Q3 25
$164.1M
$255.0M
Q2 25
$154.7M
$272.0M
Q1 25
$346.2M
$267.0M
Q4 24
$367.0M
$298.0M
Q3 24
$362.0M
$327.0M
Q2 24
$355.1M
$295.0M
Q1 24
$331.9M
$344.0M
Total Debt
NEO
NEO
ULS
ULS
Q4 25
$341.9M
$491.0M
Q3 25
$544.0M
Q2 25
$608.0M
Q1 25
$653.0M
Q4 24
$541.1M
$742.0M
Q3 24
$797.0M
Q2 24
$810.0M
Q1 24
$879.0M
Stockholders' Equity
NEO
NEO
ULS
ULS
Q4 25
$836.6M
$1.3B
Q3 25
$838.3M
$1.2B
Q2 25
$854.0M
$1.1B
Q1 25
$888.3M
$970.0M
Q4 24
$902.3M
$904.0M
Q3 24
$908.2M
$872.0M
Q2 24
$915.9M
$769.0M
Q1 24
$923.4M
$671.0M
Total Assets
NEO
NEO
ULS
ULS
Q4 25
$1.4B
$2.9B
Q3 25
$1.4B
$2.9B
Q2 25
$1.4B
$2.9B
Q1 25
$1.6B
$2.9B
Q4 24
$1.6B
$2.8B
Q3 24
$1.6B
$2.9B
Q2 24
$1.6B
$2.7B
Q1 24
$1.6B
$2.8B
Debt / Equity
NEO
NEO
ULS
ULS
Q4 25
0.41×
0.39×
Q3 25
0.46×
Q2 25
0.56×
Q1 25
0.67×
Q4 24
0.60×
0.82×
Q3 24
0.91×
Q2 24
1.05×
Q1 24
1.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEO
NEO
ULS
ULS
Operating Cash FlowLast quarter
$1.3M
$144.0M
Free Cash FlowOCF − Capex
$-6.5M
$86.0M
FCF MarginFCF / Revenue
-3.4%
10.9%
Capex IntensityCapex / Revenue
4.1%
7.4%
Cash ConversionOCF / Net Profit
2.15×
TTM Free Cash FlowTrailing 4 quarters
$-21.8M
$403.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEO
NEO
ULS
ULS
Q4 25
$1.3M
$144.0M
Q3 25
$8.9M
$155.0M
Q2 25
$20.3M
$147.0M
Q1 25
$-25.3M
$154.0M
Q4 24
$9.8M
$130.0M
Q3 24
$9.2M
$150.0M
Q2 24
$13.9M
$103.0M
Q1 24
$-25.9M
$141.0M
Free Cash Flow
NEO
NEO
ULS
ULS
Q4 25
$-6.5M
$86.0M
Q3 25
$570.0K
$109.0M
Q2 25
$14.0M
$105.0M
Q1 25
$-29.8M
$103.0M
Q4 24
$-1.8M
$72.0M
Q3 24
$-1.6M
$84.0M
Q2 24
$814.0K
$47.0M
Q1 24
$-31.5M
$84.0M
FCF Margin
NEO
NEO
ULS
ULS
Q4 25
-3.4%
10.9%
Q3 25
0.3%
13.9%
Q2 25
7.7%
13.5%
Q1 25
-17.8%
14.6%
Q4 24
-1.0%
9.7%
Q3 24
-0.9%
11.5%
Q2 24
0.5%
6.4%
Q1 24
-20.2%
12.5%
Capex Intensity
NEO
NEO
ULS
ULS
Q4 25
4.1%
7.4%
Q3 25
4.4%
5.9%
Q2 25
3.5%
5.4%
Q1 25
2.7%
7.2%
Q4 24
6.7%
7.8%
Q3 24
6.4%
9.0%
Q2 24
8.0%
7.7%
Q1 24
3.6%
8.5%
Cash Conversion
NEO
NEO
ULS
ULS
Q4 25
2.15×
Q3 25
1.55×
Q2 25
1.62×
Q1 25
2.30×
Q4 24
1.60×
Q3 24
1.70×
Q2 24
1.02×
Q1 24
2.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEO
NEO

Client Direct Billing$133.4M70%
Commercial Insurance$31.4M17%
Medicare And Other Governmental$25.4M13%

ULS
ULS

Industrial$352.0M45%
Ongoing Certification Services$259.0M33%
Software And Advisory$102.0M13%
Software$75.0M10%

Related Comparisons